J Korean Endocr Soc.  2007 Aug;22(4):252-256. 10.3803/jkes.2007.22.4.252.

Diagnosis and Treatment of Polycystic Ovary Syndrome

• Lee H
• Sung YA

• KMID: 2063533
• DOI: http://doi.org/10.3803/jkes.2007.22.4.252

Abstract

No abstract available.

MeSH Terms

Diagnosis*
Polycystic Ovary Syndrome*

Reference

1. Sam S, Dunaif A. Polycystic ovary syndrome: Syndrome XX? Trends Endocrinol Metab. 2003. 14:365–370.

2. Ehrmann D. polycystic ovary syndrome. N Eng J Med. 2005. 352:1223–1236.

3. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol. 2002. 174:1–5.

4. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab. 2006. 91:1660–1666.

5. Rosenfield RL. Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007. 92:787–796.

6. de Zegher F, Ibáñez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril. 2006. 86:Suppl 1. S4–S5.

7. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004. 19:41–47.

8. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006. 20:193–205.

9. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006. 91:4237–4245.

10. Byun EK, Kim HJ, Oh J-Y, Hong YS, Sung Y-A. The prevalence of polycystic ovary syndrome in college students from Seoul. J Kor Soc Endocrinol. 2005. 20:120–126.

11. Byun GW, Choi YJ, Lee HJ, Oh J-Y, Hong YS, Sung Y-A, Chung HW. Phenotypic variation of polycystic ovary syndrome. J Kor Endocrine Soc. (in press).

12. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003. 24:302–312.

13. Vignesh JP, Mohan V. Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med. 2007. 53:128–134.

14. Lee HJ, Oh J-Y, Hong YS, Sung Y-A, Chung HW. Prevalence of metabolic syndrome in young Korean women with polycystic ovary syndrome. J Kor Diabetes Assoc. 2006. 30:285–291.

15. Krysiak R, Okopień B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep. 2006. 58:614–625.

16. Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril. 2006. 86:1447–1451.

17. Oh J-Y, Byun EK, Park HR, Choi YJ, Kim HJ, Lee HJ, Hong YS, Sung Y-A, Chung HW. Therapeutic Effects of Metformin and Rosiglitazone in Korean Women with Polycystic Ovary Syndrome. J Kor Soc Endocrinol. 2005. 20:467–475.

18. Legro RS, Barnhart HX, Schlaff WD, et al. Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007. 356:551–566.